Causal AI can substantially improve the value of polygenic risk score for CVD
This video was recorded at the Congress of the American College of Cardiology (ACC) 2023 in New Orleans, LA, USA.
Brian A. Ference, M.D, Professor and Director of Research in Translational Therapeutics, Executive Director, Centre for Naturally Randomized Trials, University of Cambridge, United Kingdom
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Share this page with your colleagues and friends: